

## Contents

### Volume 25, 1991

Volume 25, Number 1

1991

#### CONTENTS

- |                               |    |  |
|-------------------------------|----|--|
| <b>Robert J. Temple</b>       | 1  | Access, Science, and Regulation                    |
| <b>P. Blake</b>               | 13 | Can We Accelerate Drug Development?                |
| <b>M. J. Ratcliffe</b>        |    |  |
| <b>Alan Gelberg</b>           | 19 | Technological Developments with the FDA Adverse    |
| <b>George D. Armstrong</b>    |    | Drug Reaction File System                          |
| <b>Michael W. Dreis</b>       |    |  |
| <b>Charles Anello</b>         |    |  |
| <b>Tom A. Hutchinson</b>      | 29 | Computerized Aids for Probabilistic Assessment of  |
| <b>A. Philip Dawid</b>        |    | Drug Safety I: A Spreadsheet Program               |
| <b>David J. Spiegelhalter</b> |    |  |
| <b>Robert G. Cowell</b>       |    |  |
| <b>Sue Roden</b>              |    |  |
| <b>Tom A. Hutchinson</b>      | 41 | Computerized Aids for Probabilistic Assessment of  |
| <b>A. Philip Dawid</b>        |    | Drug Safety II: An Expert System                   |
| <b>David J. Spiegelhalter</b> |    |  |
| <b>Robert G. Cowell</b>       |    |  |
| <b>Sue Roden</b>              |    |  |
| <b>Beverly M. DeVries</b>     | 49 | Screening for Illicit Drug Use in Drug Development |
| <b>George S. Hughes, Jr</b>   |    | Studies  |
| <b>Linda S. Huyser</b>        |    |  |
| <b>Chih-Wu Chang</b>          | 55 | Automated Information Delivery in a Pharmaceutical |
| <b>John G. Caster</b>         |    | Company  |
| <b>Jed C. Morris</b>          |    |  |
| <b>Roger P. Nelson</b>        |    |  |
| <b>David L. Larson</b>        |    |  |
| <b>Joseph A. Tangrea</b>      | 63 | A Method for the Detection and Management of       |
| <b>Maria Elena Adrianza</b>   |    | Adverse Events in Clinical Trials                  |
| <b>Mary McAdams</b>           |    |  |

<b>Gene S. Gilbert</b> <b>Naitee Ting</b> <b>Lonni Zubkoff</b>	81	A Statistical Comparison of Drug Safety in Controlled Clinical Trials: The Genie Score as an Objective Measure of Lab Abnormalities
<b>Michael C. Joseph</b> <b>Kathy Schoeffler</b> <b>Peggy A. Doi</b> <b>Helen Yefko</b> <b>Cindy Engle</b> <b>Erika F. Nissman</b>	97	An Automated COSTART Coding Scheme
<b>Mary Ann F. Kirkpatrick</b>	109	Factors that Motivate Healthy Adults to Participate in Phase I Drug Trials
<b>Mickey C. Smith</b> <b>Julie A. Fisher</b>	115	A Computerized Bibliography of Research on Medication Use Studies (MUST)
<b>Robert M. Bell</b>	123	Welcome and Introduction
<b>Joyce A. Generali</b>	125	Adverse Drug Reactions: Communications and Reporting—Hospital and Home Health Care Perspectives
<b>G. Edward Collins</b>	131	Adverse Drug Experience Communications and Reporting Industry Perspective: Regulations and Practice
<b>Karen Overstreet Price</b> <b>Jack M. Rosenberg</b> <b>Martha M. Rumore</b>	139	Fee-for-Service and Cost Justification Activities of Pharmacist-manned Drug Information Centers in the United States
<b>J. Anne Milochik</b>	155	Information Technologies—Challenges of the 1990s: A Company View
	161	Erratum
	I	Software Survey Section: <i>BBAC—Blood and Breath Alcohol Concentrations</i>

## CONTENTS

**The Management of Adverse Experience Information:  
Phase 1 Through Epidemiology**

<b>Raymond L. Herman</b>	163	Opening Remarks
<b>A. D. Dayan</b>	165	The Limitations of Animal Studies: What Can and Cannot Be Predicted for Man
<b>Michael L'E. Orme</b> <b>Philip A. Routledge</b> <b>John D. Harry</b>	171	The Safety of Phase I Studies: A Study of Healthy Volunteer Studies in Great Britain Over a 12-Month Period
<b>Judith Kramer LittleJohn</b> <b>Deborah Otcasek Lucas</b> <b>Gail Batson-Fowler</b> <b>Suzanne Edwards</b>	175	Adverse Experience Collection: Perspective from a Biological Development Program
<b>Patrick C. Waller</b>	181	Postmarketing Surveillance: The Viewpoint of a Newcomer to Pharmacoevidemiology
<b>M. J. S. Langman</b>	187	Postmarketing Surveillance: The Problems of Confounded Conclusions
<b>Susan M. Wood</b>	191	Postmarketing Surveillance: Viewpoint from a Regulatory Authority
<b>Margaret M. Westland</b>	197	Coding: The Mortar in the Bricks of Data Analysis
<b>Charles Matsumoto</b>	201	Implementation and Use of the COSTART Dictionary at Lilly: Would We Do It Again?
<b>Paul A. Litka</b>	205	Labeling Development: Incorporation of Safety Information
<b>Garth K. Graham</b>	211	Labeling: What Should It Say, and How Should It Say It?
<b>Jeffrey B. Margulies</b>	217	Epidemiologic Causation in the Courtroom: Square Pegs in Round Holes?
<b>Jan Venulet</b>	229	APWI: Past and Present

- Tom A. Hutchinson** 235 Computerized Bayesian ADE Assessment
- Claudio A. Naranjo** 243 Microcomputer-Assisted Bayesian Differential  
**Krista L. Lanctôt** Diagnosis of Severe Adverse Reactions to New  
Drugs: A 4-Year Experience
- Christian Benichou** 251 Experts' Opinion in Causality Assessment: Results of  
**Gaby Danan** Consensus Meetings

**Additional Articles  
of Significant Interest**

- J. M. Antonello** 257 An Automated System for the Statistical Evaluation  
**J. F. Heyse** of Developmental Toxicology  
**D. J. Verbinski**  
**J. L. Ebbenga**  
**J. A. Trojnar**  
**R. L. Clark**
- Ross H. Weaver** 269 The Role of Information Technology in ICI  
**KT Porter** Pharmaceuticals Group Medical Information  
Department
- Robert M. Sturm** 275 Strategic Uses of Information Technology in Clinical  
Research
- Harvey Gurien** 285 A Module System for the Preparation of International  
Dossiers, Manufacturing, and Controls (New  
Chemical Entities)
- Jack Faricelli** 289 Analysis and Reporting Windows for Clinical Trial  
**Gregory L. Lazarev** Information
- Frank A. Adornato** 295 Worldwide Drug Planning System: An Automated  
**Stephan J. Bachmann** System of Registration Requirements and Its  
**Lyse DeMontigny** Application for Regulatory Planning and Strategies  
**Pamela Corsentino**  
**Gail Lowden**  
**Terry Jamieson**  
**Linda G. Brown**

**I Software Survey Section:  
PREACC**

## CONTENTS

## Part I

**Articles Developed From the DIA Workshop on Statistical Issues in the Pharmaceutical Industry: Analysis of Reporting of Phase III Clinical Trials Including Kinetic/Dynamic Analysis and Bayesian Analysis**

<b>W. A. T. Archambault</b>	305	Introduction
<b>Lilly P. Sanathanan</b>	307	Random Effects Modeling in Population: Kinetic/Dynamic Analysis
<b>Lewis B. Sheiner</b> <b>Raymond J. Lipicky</b>	319	Population PK/PD Analysis
<b>P. I. Feder</b> <b>C. T. Olson</b> <b>D. W. Hobson</b> <b>M. C. Matthews</b> <b>R. L. Joiner</b>	323	Statistical Analysis of Dose-Response Experiments by Maximum Likelihood Analysis and Iteratively Reweighted Nonlinear Least Squares Regression Techniques
<b>James F. Ward</b> <b>Ronald V. Nardi</b>	335	Using Early Drug Development Data to Design Phase III Trials
<b>Donald A. Berry</b>	345	Bayesian Methods in Phase III Trials
<b>A. Lawrence Gould</b>	369	Using Prior Findings to Augment Active-Controlled Trials and Trials With Small Placebo Groups
<b>Michael D. Hughes</b>	381	Practical Reporting of Bayesian Analyses of Clinical Trials
<b>Jonathan B. Skinner</b>	395	On Combining Studies
<b>William H. Stewart</b> <b>Kerry B. Hafner</b>	405	Statistical Analysis of Trough/Peak Ratios

<b>Dennis Gillings</b> <b>Gary Koch</b>	411	The Application of the Principle of Intention-To-Treat to the Analysis of Clinical Trials
<b>Lilly P. Sanathanan</b> <b>Carl Peck</b> <b>Robert Temple</b> <b>Ron Lieberman</b> <b>Gordon Pledger</b>	425	Randomization, PK-Controlled Dosing, and Titration: An Integrated Approach for Designing Clinical Trials
<b>Gary G. Koch</b>	433	Summary and Discussion

## Part II

### Statistics in the Analysis of Safety Data

<b>Gregory G. Enas</b>	439	Making Decisions About Safety in Clinical Trials — The Case for Inferential Statistics
<b>William J. Huster</b>	447	Clinical Trial Adverse Events: The Case for Descriptive Techniques
<b>W. James Alexander</b>	457	Adverse Events: A Classification System for Use in Clinical Trials
<b>Gary G. Koch</b>	461	Discussion: Statistical Perspective
	I	Software Survey Section: "N"

---

Volume 25, Number 4

October–December, 1991

## CONTENTS

<b>David A. Kessler</b>	465	Remarks—1991 Annual DIA Meeting
<b>A. C. Cartwright et al</b>	471	International Harmonization and Consensus DIA Meeting on Bioavailability and Bioequivalence Testing Requirements and Standards

**Articles Developed from the DIA Workshop on Integrated Safety Summary**

- |                             |     |   |
|-----------------------------|-----|---|
| <b>David M. Cocchetto</b>   | 483 | Preface: Preparation of an Integrated Safety Summary for a New Drug Application |
| <b>Cheryl F. Graham</b>     |     |   |
| <b>Robert J. Temple</b>     | 485 | The Regulatory Evolution of the Integrated Safety Summary                       |
| <b>Charles Lineberry</b>    | 493 | Approaches to Describing Common Adverse Events in the Integrated Safety Summary |
| <b>Thomas Q. Garvey III</b> | 501 | Can There Really Be an Integrated Safety Summary?                               |

**Additional Articles of Significant Interest**

- |                          |     |  |
|--------------------------|-----|--|
| <b>Charles F. Curran</b> | 513 | A Multidrug Patient Assistance Program   |
| <b>Diane Chen</b>        | 523 | All You Ever Wanted to Know About a CPMP Hearing—A DRA Professional's Guide into the Unknown |
| <b>Gerald A. Faich</b>   | 531 | Postmarketing Surveillance: Lessons Learned  |
| <b>John L. Turner</b>    | 537 | The Implementation of European Community Directives Concerning GMP                           |
| <b>Ronald D. Mann</b>    | 545 | Monitoring Safety with Particular Reference to the European Community                        |
| <b>Léon Gauci</b>        | 551 | Meeting Summary Report: Biotechnology and Drug Development                                   |
| <b>C. Benichou</b>       | 565 | Guidelines for the Management of Adverse Events Occurring During Clinical Trials             |
| <b>G. Danan</b>          |     |  |
| <b>Charles F. Curran</b> | 573 | A System for Managing Medical and Technical Information                                      |
| <b>Larry M. Hagerman</b> |     |  |
| <b>Betty R. Kuhnert</b>  | 579 | International Approval Process for Clinical Documents  |

<b>Harold K. Pickering</b>	585	In-House Mechanisms for Handling Products Liability Litigation
<b>Yves Juillet</b>	591	Industry Health Authorities Relationships in Pharmacovigilance (PMS): The French Situation
<b>James D.Cope</b>	595	Self-Care/Self-Medication: Where Are We Headed?
<b>Annie L. Britt</b> <b>Deanne E. Knapp</b> <b>Charles Anello</b> <b>Zollie A. Perry</b>	599	Completeness of Adverse Drug Experience Reporting by Manufacturers to the FDA
<b>Albert Weissman</b>	607	Inferring Drug Efficacy Based on Data from One Subject
	I	Software Survey Section
	V	Volume 25 Contents and Author Index



